Molecular Formula: C₅₀H₆₈N₁₄O₁₀
Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
Molecular Weight: 1025.182 g/mol
PubChem CID: 9941379 | CAS Number: 189691-06-3
Purity: >99% | Vial Size: 10mg | Storage: -20°C, protect from light
 
Product Overview
PT-141 (Bremelanotide) represents a breakthrough synthetic melanocortin derivative engineered from alpha-melanocyte-stimulating hormone. This heavily modified peptide functions as a selective agonist for melanocortin-4 (MC-4R) and melanocortin-1 (MC-1R) receptors, offering unique research applications in sexual dysfunction, hemorrhagic shock, immune modulation, and cancer prevention. Unlike conventional treatments targeting peripheral blood flow, PT-141 works through central nervous system mechanisms.
Revolutionary Melanocortin Mechanism
PT-141 uniquely stimulates MC-4R in the CNS, producing sexual arousal and influencing behavior through neurological pathways rather than vascular mechanisms. This central action enables treatment of sexual dysfunction stemming from psychological or neurological causes rather than blood flow limitations. Additionally, MC-1R binding provides anti-inflammatory, anti-fungal, and DNA repair pathway activation.
Primary Research Applications
Sexual Dysfunction Research
PT-141 demonstrates exceptional efficacy in both male and female sexual dysfunction studies. Clinical trials show roughly one-third of sildenafil-resistant erectile dysfunction patients achieved adequate erection for intercourse via nasal administration. Female studies revealed increased satisfying sexual events per month with decreased sexual distress scores without substantial side effects.
Hemorrhagic Shock Research
Modified PT-141 (PL-6983) shows promise for hemorrhagic shock treatment. MC-1R and MC-4R binding reduces ischemia and protects tissues against inadequate blood supply during hypovolemic shock. Phase IIb trials demonstrated intravenous administration produces minimal side effects while providing tissue protection.
Anti-Fungal Research
MC-1R demonstrates important anti-fungal and anti-inflammatory properties in fungal infection models. This offers alternative mechanisms for treating resistant fungal infections, particularly valuable for immune-compromised patients where current anti-fungals produce treatment-limiting side effects.
Cancer Research Applications
MC-1R serves as crucial DNA repair pathway stimulus, making PT-141 valuable for cancer treatment and prevention research. Studies show MC-1R variants increase basal cell and squamous cell carcinoma risk. Modified PT-141 may correct variant-related problems and provide protective mechanisms.
Obesity Research
MC-4R defects account for approximately 6% of early-onset obesity cases. PT-141 offers unique means of exploring MC-4R-related obesity causes and potential interventions through receptor pathway restoration.
Clinical Development History
Sexual Dysfunction Trials: Advanced through Phase IIb trials for hypoactive sexual desire disorder (HSDD) in women, showing statistical significance in sexual satisfaction metrics before being initially discontinued due to regulatory endpoint challenges.
Rekynda Development: 2017 Phase II Reconnect trials launched using subcutaneous PT-141 injections for female sexual dysfunction, incorporating modified endpoints advocated by FSD experts.
Multi-Indication Research: Ongoing investigations span hemorrhage treatment, immune function, pain/inflammation pathways, and kidney pathology applications.
Research Advantages
Central Mechanism: CNS-mediated effects bypass peripheral limitations
Dual Receptor Activity: MC-1R and MC-4R targeting provides multi-system benefits
Dose-Dependent Response: Strong dose-response relationships in clinical studies
Alternative Pathway: Different mechanism from conventional treatments
Multi-System Applications: Sexual, cardiovascular, immune, and metabolic research
Excellent Bioavailability: Superior subcutaneous absorption, minimal oral bioavailability
Safety Profile & Bioavailability
Preclinical studies demonstrate minimal side effects with excellent subcutaneous bioavailability. Clinical trials report manageable adverse effects primarily limited to mild nausea and flushing. The peptide's selective receptor targeting contributes to favorable safety characteristics compared to broader-acting compounds.
Quality Specifications
Every PT-141 batch undergoes comprehensive quality control:
HPLC purity analysis confirming >99% purity
Mass spectrometry molecular weight verification (1025.182 g/mol)
Amino acid sequence confirmation
Endotoxin testing (<1.0 EU/mg)
USP sterility testing standards
Certificate of Analysis provided with shipment
Storage & Reconstitution
Store lyophilized powder at -20°C in original sealed vials. Protect from light, heat, and humidity. Reconstitute with bacteriostatic water or sterile saline immediately before use. Once reconstituted, use within 24 hours or store at -80°C for short-term use. Avoid repeated freeze-thaw cycles.
Research Protocol Applications
Sexual dysfunction mechanism studies
Hemorrhagic shock protection research
Anti-fungal immunity investigations
Cancer prevention pathway research
Obesity and metabolic dysfunction studies
Pain and inflammation research
Kidney pathology investigations
DNA repair mechanism studies
Research Applications Summary
Male and female sexual dysfunction research
Hemorrhagic shock and tissue protection studies
Anti-fungal and immune system research
Cancer prevention and DNA repair studies
Obesity and MC-4R deficiency research
Pain, inflammation, and kidney pathology
Central nervous system mechanism studies
Alternative therapeutic pathway research
Regulatory Compliance
PT-141 is manufactured under strict GMP conditions exclusively for research purposes. This product is intended solely for laboratory and scientific research applications and is not approved for human consumption, therapeutic use, or clinical applications. Researchers must comply with institutional guidelines and obtain appropriate ethics committee approvals.
Research Use Only: Not for human or veterinary therapeutic applications. Handle according to laboratory safety protocols and institutional research guidelines.